University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial SWOG-S1801


A phase II randomized study of adjuvant versus neoadjuvant MK-3475 (pembrolizumab) for clinically detectable stage III-IV high risk melanoma

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Other
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Gino In, M.D.-Fellow
Other Trial Staff:  Charlean Ketchens, Coordinator, Marile Garcia, Coordinator, Shamim Jhimlee, Coordinator, Yanli Wang, D.M., Laurie De Oliveira, Coordinator, Rabia Rehman, Coordinator, Diana Oganyesyan, Coordinator, Janelle Luevano, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.